Skip to main content
SpringerLink
Log in

Effects of celiprolol vs. nifedipine on serum lipoproteins in patients with mild to moderate hypertension

  • Lipoproteins
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

During a double-blind, randomized study in hypertensive patients, changes in plasma lipid and lipoprotein levels during treatment with celiprolol were compared with those occurring during nifedipine treatment. Fifty-three patients (28 men and 25 women) with mild-to-moderate hypertension, aged 20–64 years, were studied. After a 1-month placebo run-in period, patients were randomly assigned to receive either nifedipine (40 mg daily) or celiprolol (200 mg daily), each time using a double-dummy technique. After 6 weeks, dosages of each drug could be doubled. After 6 weeks, there were no differences in plasma lipids between the two treatment groups. However, the changes after 12 weeks of treatment were different (p<0.05) between the groups, leading to lower levels of plasma esterified cholesterol, low-density lipoprotein (LDL) cholesterol, and apoprotein AI, AII, and B in the celiprolol group. Plasma lecithin cholesterol acyltransferase activity (LCAT) was not modified. The present study showed that celiprolol was at least equivalent to nifedipine in terms of secondary effects on plasma lipids and lipoprotein.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pruss TP, Khandwala A, Wolf PS, et al. Celiprolol: A new beta-adrenoceptor antagonist with novel ancillary properties.J Cardiovasc Pharmacol 1986;8(Suppl 4):s29-s32.

    Google Scholar 

  2. Milne RJ, Buckley MM. Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease.Drugs 1991;41:941–969.

    PubMed  Google Scholar 

  3. Herrman JM, Mayer EO. A long-term study of the effects of celiprolol on blood pressure and lipid-associated risk factors.Am Heart J 1988;116:1416–1421.

    PubMed  Google Scholar 

  4. Sirtori CR, Johnson B, Caccarino V, et al. Lipid effects of celiprolol, a new cardioselective beta-blocker, versus propranolol.Clin Pharmacol Ther 1989;45:617–626.

    PubMed  Google Scholar 

  5. Fogari R, Zoppi A, Poletti L, et al. Plasma lipids during chronic antihypertensive therapy with different beta-blockers.J Cardiovasc Pharmacol 1989;14(Suppl 7):s28-s32.

    Google Scholar 

  6. Weidmann P, Uehlinger DE, Gerber A. Antihypertensive treatment and serum lipoproteins. Editorial review.J Hypertens 1985;3:297–306.

    PubMed  Google Scholar 

  7. Lopes-Virella MF, Stone M, Ellis S, Colwell JA. Cholesterol determination in high density lipoproteins separated by three different methods.Clin Chem 1977;23:882–884.

    PubMed  Google Scholar 

  8. Dobiasova M. Lecithin cholesterol acyltransferase and the regulation of endogenous cholesterol transport.Adv Lipid Res 1983;20:107–194.

    PubMed  Google Scholar 

  9. Friedewald WT, Levy RI, Fredrikson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge.Clin Chem 1972;18:499–502.

    PubMed  Google Scholar 

  10. Kannel WB. Influence of multiple risk factors on the hazard of hypertension.J Cardiovasc Pharmacol 1990;16(Suppl 5):s53-s57.

    PubMed  Google Scholar 

  11. Amery A, Fagard R, Staessen J. Recent data on changes in lipid metabolism induced by hypotensive drugs.Curr Opin Cardiol 1987;2:769–774.

    Google Scholar 

  12. Goto Y, Tamachi H. Antihypertensive therapy and the lipid risk factor. In: Bühler FR, Laragh JH, eds.Handbook of Hypertension, Volume 13: The Management of Hypertension. Amsterdam: Elsevier, 1990:362–378.

    Google Scholar 

  13. Van Brummelen P. The relevance of intrinsic sympathomimetic activity for beta-blocker-induced changes in plasma lipids.J Cardiovasc Pharmacol 1983;5:S51-S55.

    PubMed  Google Scholar 

  14. Schaefer EJ, Levy RI. Pathogenesis and management of lipoprotein disorders.N Engl J Med 1985;312:1300–1310.

    PubMed  Google Scholar 

  15. Desager JP, Horsmans Y, Harvengt C. Lecithin: Cholesterol acyltransferase activity in familial hypercholesterolemia treated with simvastatin and simvastatin plus low-dose colestipol.J Clin Pharmacol 1991;31:537–542.

    PubMed  Google Scholar 

  16. Lohmann FW, Loesment WA, Kaehler H. Beta-receptor blockade, physical activity and metabolism.J Cardiovasc Pharmacol 1990;16(Suppl 5):s45-s52.

    Google Scholar 

  17. Lijnen P. Biochemical mechanisms involved in the β-blocker induced changes in serum lipoproteins.Am Heart J 1992;124:549–556.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular Research, University of Leuven, Leuven, Belgium

    P. Lijnen, R. Van Hoof & A. Amery

Authors
  1. P. Lijnen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Van Hoof
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Amery
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lijnen, P., Van Hoof, R. & Amery, A. Effects of celiprolol vs. nifedipine on serum lipoproteins in patients with mild to moderate hypertension. Cardiovasc Drug Ther 8, 509–513 (1994). https://doi.org/10.1007/BF00877929

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00877929

Key Words

Search

Navigation